MedTrace Logo

Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults

NCT02822547 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 253

Last updated 2016-07-04

No results posted yet for this study

Summary

Patients will receive Peginterferon alfa-2a according to the standard medical practice but the observation period is 12 weeks

Conditions

Interventions

DRUG

Peginterferon alfa-2a

Patients will receive Peginterferon alfa-2a according to the standard medical practice

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Yonsei University

    lead OTHER

Principal Investigators

  • Sang Hoon Ahn · Severance Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-09-30
Completion
2016-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02822547 on ClinicalTrials.gov